About Us
Mission Statement
Ritter Pharmaceuticals’ mission is to allow others the freedom and enjoyment of eating foods without fear or embarrassment of digestive distress.
Ritter is thus committed to the discovery, development and commercialization of novel therapeutic treatments for gastrointestinal diseases and conditions.
Science
The company’s scientific platform of gastrointestinal physiology, metabolism and gut adaptation brings creativity to providing unique therapeutic approaches to a variety of GI diseases, including lactose intolerance, irritable bowel syndrome, Crohn’s disease, and ulcerative colitis.
Ritter’s first compound, RP-G28, has been developed for the treatment of lactose intolerance. RP-G28 will effectively stand out as the first FDA-approved drug for the treatment of lactose intolerance.
Founder’s Story
Founder Andrew Ritter become severely lactose intolerant in the early 1990s. Any slight consumption of dairy would cause embarrassing and painful digestive symptoms. Doctors told Mr. Ritter the only solution was to stay away from dairy, however avoiding dairy products all together was very difficult for him. Mr. Ritter became frustrated with the amount of unforeseen hidden dairy foods in products and eating out at restaurants and events were very difficult. The disease literally controlled his life, affected his social life and his health.
Mr. Ritter could not comprehend why physicians did not have a better solution for the over 50 million sufferers of lactose intolerance. Thus, he set off contacting and recruiting the best and brightest gastrointestinal and lactose intolerance experts from around the country to study, learn and develop a better solution to lactose intolerance.
RP-G28 has been developed after over 12 years of painstaking developmental and testing. Mr. Ritter and his team have evaluated thousands of lactose intolerant sufferers from around the world and have complied comprehensive data and analysis on patient behaviors, physician responses, market trends and gut physiology.